[1] Lin C, Song W, Bi X, et al.Recent advances in the ARID family: focusing on roles in human cancer[J]. Onco Targets Ther, 2014,7: 315-324.
[2] Zhao J, Chem J, Lin H, et al.The clinicopathologic significance of BAF250a (ARID1A) expression in hepatocellular carcinoma[J]. Pathol Oncol Res, 2016, 22(3): 453-459.
[3] Nault JC, Martin Y, Caruso S, et al.Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma[J]. Hepatology, 2020, 71(1): 164-182.
[4] Khemlina G, Ikeda S, Kurzrock R.The biology of hepatocellular carcinoma: implications for genomic and immune therapies[J]. Molecular Cancer, 2017, 16(1): 149-158.
[5] Otto JE, Kadoch C.A two-faced mSWI/SNF subunit: dual roles for ARID1A in tumor suppression and Oncogenicity in the liver[J]. Cancer Cell, 2017, 32(5): 542-543.
[6] He F, Li J, Xu JF, et al.Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2015, 34(1): 47-54.
[7] Samarizis EP, Gutsche K, Dedes KJ, et al.Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition[J]. Oncotarget, 2014, 5(14): 5295-5303.
[8] Hu C, Li W, Tian F, et al.Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 68(3): 465-475.
[9] Trizzino M, Barbieri E, Petracovici A, et al.The tumor suppressor ARID1A controls global transcription via pausing of RNA polymerase II[J]. Cell Reports, 2018, 23(13): 3933-3945.
[10] Fujimoto A, Totoki Y, Abe T, et al.Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators[J]. Nat Genet, 2012, 44(7): 760-764.
[11] Watanabe R, Ui A, Kanno S, et al.SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability[J]. Cancer Res, 2014, 74(9): 2465-2475.
[12] Tordella L, Khan S, Hohmeyer A, et al.SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer[J]. Genes Dev, 2016, 30(19): 2187-2198.
[13] Ramos-lopez O, Riezu-boj JI, Milagro FI, et al. Association of methylation signatures at hepatocellular carcinoma pathway genes with adiposity and insulin resistance phenotypes[J]. Nutr Cancer, 2019, 71(5): 840-851.
[14] Liu L, Tian N, Zhou C, et al.A potentially functional variant of ARID1B interacts with physical activity in association with risk of hepatocellular carcinoma[J]. Oncotarget, 2017, 8(19): 31057-31064.
[15] Khazanchi R, Ronspies CA, Smith SC, et al.Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss-of-function disorder,a SWI/SNF-related intellectual disability[J]. Am J Med Genet A, 2019, 179(5): 808-812.
[16] 高庆祝,汪凯,梁利,等.基于CRISPR/Cas9 系统构建 ARID2 基因敲除模型并探索其对肝癌细胞增殖和迁移能力的影响[J]. 重庆医科大学学报, 2017,42(7): 850-855.
[17] Duan Y, Tian L, Gao Q, et al.Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression[J]. Oncotarget, 2016, 7(29): 45863-45875.
[18] Oba A, Shimada S, Akiyama Y, et al.ARID2 modulates DNA damage response in human hepatocellular carcinoma cells[J]. J Hepatol, 2017, 66(5): 942-951.
[19] Liu X, Liao W, Yuan Q, et al.TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells[J]. Oncotarget, 2015, 6(33): 34309-34320.
[20] Zhang L, Wang W, Li X, et al.MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2[J]. Int J Oncol, 2016, 48(6): 2425-2434.
[21] Wang Y, Chang W, Chang W, et al.MicroRNA-376c-3p facilitates human hepatocellular carcinoma progression via repressing AT-rich interaction domain 2[J]. J Cancer, 2018, 9(22): 4187-4196.
[22] Yu P, Wu D, You Y, et al.miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression[J]. Exp Cell Res, 2015, 336(2): 232-241.
[23] Llovet JM, Zucman-Rossi J, Pikarsky E, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2:16018.
[24] 姬旭慧,张玲,张江波,等.原发性肝细胞癌细胞系和组织中ARID2的表达[J].郑州大学学报(医学版),2013,48(6):786-788.
[25] 李治,陈震,段玉洁,等.乙型肝炎病毒复制对肝癌细胞Arid2基因表达的影响[J].重庆医科大学学报,2015,40(3):344-349.
[26] Gao Q, Wang K, Chen K, et al.HBx protein‐mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma[J]. Cancer Sci, 2017, 108(7): 1328-1337.
[27] Wang R, Yu Z, Chen F, et al.Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma[J]. Human Pathol, 2018, 73: 114-121.
[28] Xiang Y, Zhu Z, Han G, et al.JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer[J]. Proc Natl Acad Sci USA, 2007, 104(49): 19226-19231.
[29] Tang B, Qi G, Tang F, et al.JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells[J]. Oncotarget, 2015, 6(14): 12723.
[30] Wang D, Han S, Peng R, et al.Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27[J]. J Exp Clin Cancer Res, 2016, 35(1): 37.
[31] Shigekawa Y, Hayami S, Ueno M, et al.Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma[J]. Oncotarget, 2018, 9(76): 34320-34335.
[32] Wang X, Oishi N, Shimakami T, et al.Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B[J]. World J Gastroenterol, 2017, 23(18): 3252-3261. |
